TY - JOUR
T1 - SIU-ICUD recommendations on bladder cancer
T2 - systemic therapy for metastatic bladder cancer
AU - Merseburger, Axel S.
AU - Apolo, Andrea B.
AU - Chowdhury, Simon
AU - Hahn, Noah M.
AU - Galsky, Matthew D.
AU - Milowsky, Matthew I.
AU - Petrylak, Daniel
AU - Powles, Tom
AU - Quinn, David I.
AU - Rosenberg, Jonathan E.
AU - Siefker-Radtke, Arlene
AU - Sonpavde, Guru
AU - Sternberg, Cora N.
N1 - Publisher Copyright:
© 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2019/1/23
Y1 - 2019/1/23
N2 - The SIU (Société Internationale d’Urologie)–ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe.
AB - The SIU (Société Internationale d’Urologie)–ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe.
KW - Bladder cancer
KW - Checkpoint inhibitors
KW - Chemotherapy immunotherapy
KW - Urothelial cancer
UR - http://www.scopus.com/inward/record.url?scp=85053830234&partnerID=8YFLogxK
U2 - 10.1007/s00345-018-2486-1
DO - 10.1007/s00345-018-2486-1
M3 - Article
C2 - 30238401
AN - SCOPUS:85053830234
SN - 0724-4983
VL - 37
SP - 95
EP - 105
JO - World Journal of Urology
JF - World Journal of Urology
IS - 1
ER -